Zynova Shalby launches advanced oncology department
Zynova Shalby launches advanced oncology department – Express Healthcare
…
Read More
The Times Of Bengal
For You Forever Yours
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical…
Read More
Alert for road commuters: Buying FASTag online? NHAI flags fake annual pass websites
Home News Alert for road commuters: Buying FASTag online? NHAI flags fake annual pass websites – check details here NHAI…
Read More
Keenova Announces New Manuscript on Plantar Fibromatosis Treatment Patterns in Peer-Reviewed Journal of Foot and Ankle Surgery
Plantar fibromatosis is a rare condition, and most newly diagnosed patients receive conservative (nonsurgical) treatments. Real-world treatment patterns suggest symptoms…
Read More
Caring Senior Service caregiver named to 2025 Frontline Honors Class
The home care organization’s Caregiver of the Year, Andreanna Smith, recognized nationally for lifesaving actions and unwavering dedication to seniors…
Read More
Zemcelpro® (dorocubicel) erhält NUB-Status 1 in Deutschland
Die NUB-Einstufung für Zemcelpro® (dorocubicel) ermöglicht Krankenhäusern, umgehend eine vorübergehende, zusätzliche Vergütung für dessen Anwendung zu beantragen. MONTREAL, 16. Februar…
Read More
Zemcelpro® (dorocubicel) se voit attribué le statut 1 du programme NUB en Allemagne
La désignation NUB pour Zemcelpro® (dorocubicel) permet aux hôpitaux de demander immédiatement un remboursement complémentaire temporaire pour son utilisation. MONTRÉAL,…
Read More
Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb.…
Read More
Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb.…
Read More
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results…
Read More